MA55522A - Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial - Google Patents

Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial

Info

Publication number
MA55522A
MA55522A MA055522A MA55522A MA55522A MA 55522 A MA55522 A MA 55522A MA 055522 A MA055522 A MA 055522A MA 55522 A MA55522 A MA 55522A MA 55522 A MA55522 A MA 55522A
Authority
MA
Morocco
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
urothelial carcinoma
fgfr tyrosine
Prior art date
Application number
MA055522A
Other languages
English (en)
Inventor
Anjali Narayan Avadhani
Anne Elizabeth O'hagan
Ademi Elena Santiago-Walker
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55522A publication Critical patent/MA55522A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
MA055522A 2019-03-29 2020-03-27 Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial MA55522A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19188971 2019-07-30

Publications (1)

Publication Number Publication Date
MA55522A true MA55522A (fr) 2022-02-09

Family

ID=70296138

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055522A MA55522A (fr) 2019-03-29 2020-03-27 Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial

Country Status (15)

Country Link
US (1) US12691112B2 (fr)
EP (1) EP3946341A1 (fr)
JP (2) JP7747521B2 (fr)
KR (1) KR20210145211A (fr)
CN (1) CN113645974A (fr)
AU (1) AU2020253827B2 (fr)
BR (1) BR112021019446A2 (fr)
CA (1) CA3130460A1 (fr)
IL (1) IL286729A (fr)
JO (1) JOP20210266A1 (fr)
MA (1) MA55522A (fr)
MX (1) MX2021011926A (fr)
PH (1) PH12021552342A1 (fr)
SG (1) SG11202109902SA (fr)
WO (1) WO2020205493A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12277100B2 (en) * 2019-09-12 2025-04-15 Life Spectacular, Inc. Maintaining user privacy of personal, medical, and health care related information in recommendation systems
WO2022243467A1 (fr) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase fgfr destinés au traitement des tumeurs solides avancées
EP4719420A1 (fr) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Traitement d'un carcinome urothélial localement avancé ou métastatique avec de l'erdafinitib

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (fr) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (fr) 2005-05-23 2015-07-29 Novartis AG Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4223770A3 (fr) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Nouvelles molécules de fusion et leurs utilisations
CA2898326C (fr) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methodes de traitement du cholangiocarcinome
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3365335B1 (fr) 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒
CA3049737A1 (fr) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Traitement du cancer
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
KR20210064274A (ko) 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
BR112021015686A2 (pt) 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
US20220175768A1 (en) 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Also Published As

Publication number Publication date
US12691112B2 (en) 2026-07-28
CN113645974A (zh) 2021-11-12
JP2025156297A (ja) 2025-10-14
MX2021011926A (es) 2021-11-03
AU2020253827B2 (en) 2026-01-08
JP7747521B2 (ja) 2025-10-01
EP3946341A1 (fr) 2022-02-09
PH12021552342A1 (en) 2022-08-22
KR20210145211A (ko) 2021-12-01
AU2020253827A1 (en) 2021-09-30
IL286729A (en) 2021-10-31
WO2020205493A1 (fr) 2020-10-08
US20220054484A1 (en) 2022-02-24
SG11202109902SA (en) 2021-10-28
CA3130460A1 (fr) 2020-10-08
JOP20210266A1 (ar) 2023-01-30
JP2022527189A (ja) 2022-05-31
BR112021019446A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
MA55486A (fr) Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3665482A4 (fr) Ciblage de kinases pour le traitement de métastases cancéreuses
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP4319750A4 (fr) Polythérapies pour le traitement du cancer
EP3411073A4 (fr) Combinaisons pour le traitement du cancer
IL286729A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3990458A4 (fr) Composés pour le traitement du cancer
EP3897650A4 (fr) Polythérapie pour le traitement du cancer
EP3442564A4 (fr) Composition de proenzymes pour le traitement du cancer
EP3793548A4 (fr) Composés pour le traitement du cancer du pancréas